While early-stage biologics like LEQEMBI and KISUNLA have set a new standard for plaque clearance, the clinical pipeline is diversifying. Companies are increasingly prioritizing patient convenience through subcutaneous delivery and novel mechanisms that address agitation and cognitive decline without the sedative side effects of traditional antipsychotics.

Key emerging candidates include Suven Life Sciences' Masupirdine, a 5-HT6 antagonist currently in Phase III trials for agitation, and Roche’s Trontinemabb, which utilizes Brainshuttle technology to improve blood-brain barrier penetration. Bristol Myers Squibb’s COBENFY is also generating significant interest as a muscarinic agonist for psychosis, with potential market entry as early as 2027. Other notable assets in development include Eli Lilly’s Remternetug, Annovis Bio’s Buntanetap, and Axsome Therapeutics’ AXS-05. These therapies highlight a broader industry pivot toward personalized care, aiming to combine disease-modifying efficacy with improved long-term adherence.